<DOC>
	<DOCNO>NCT01861730</DOCNO>
	<brief_summary>Phase I/II , randomize , double-blind , placebo-controlled , safety , immunogenicity dose-range find study AERAS-404 Tuberculosis ( TB ) vaccine administer intramuscularly Bacille Calmette-Guerin ( BCG ) prim infant .</brief_summary>
	<brief_title>Phase 1/II , Safety Immunogenicity Study AERAS-404 BCG-Primed Infants</brief_title>
	<detailed_description>This Phase I/II , randomize , double-blind , placebo-controlled , safety , immunogenicity dose-range find study HIV-uninfected , HIV-unexposed , BCG-primed infant . The study vaccine AERAS-404 placebo administer without concomitant EPI vaccine ( Cohorts 1 5 , N = 159 subject ) concomitant EPI vaccine ( Cohort 6 , N = 70 subject ) . Study vaccine placebo administer single dose ( injection ) Study Day 0 ( ≥168 ≤ 196 day age , Cohorts 1 2 ) , 2-dose schedule Study Day 0 ( ≥ 168 ≤ 189 day age ) Study Day 28 ( Cohorts 3A 3B ) 3-dose schedule Study Day 0 ( ≥ 84 ≤ 98 day age ) , Study Day 42 Study Day 98 ( Cohorts 4 5 ) . Subjects Cohort 6 receive study vaccine placebo Study Day 0 ( ≥ 64 ≤ 83 day age ) , Study Day 28 ( ≥ 91 ≤ 105 day age ) , Study Day 210 ( ≥ 273 ≤ 287 day age ) . A cohort enroll safety previous cohort establish . AERAS-404 investigational vaccine manufacture Sanofi Pasteur ( SP ) Statens Serum Institute ( SSI ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Age time entry : Cohorts 1 6 Cohorts 1 2 : ≥ 168 ≤ 196 day Cohorts 3A 3B : ≥ 168 ≤ 189 day Cohorts 4 5 : ≥ 84 ≤ 98 day ( ≥ 2 week receipt EPI vaccine dose 10 week age ) Cohort 6 coincident EPI vaccine dose 10 week age ( ≥ 64 ≤ 83 day age ) 2 . Source documentation birth weight ≥ 2.5 kg . 3 . Documented BCG vaccination within 72 hour birth . 4 . Documented receipt ageappropriate EPI vaccine , except Rotavirus , Cohorts 4 6 ( see Appendix II ) . 5 . Source documentation negative HIV status mother , time pregnancy child randomization . 6 . Documentation infant HIV negative exposure infection status negative HIV ELISA HIV DNA PCR test . 7 . Parent legal guardian able willing provide sign informed consent . 8 . Participant/parent/legal guardian able attend schedule visit comply trial procedure . EXCLUSION CRITERIA 1 . History TB exposure household nonhousehold contact . 2 . History/Evidence TB disease infection . 3 . Quantiferon positive . 4 . Prior TST test . 5 . Any one Anemia , Neutropenia , Thrombocytopenia , SGPT ( ALT ) , SGOT ( AST ) Creatinine ≥ Grade 2 6 . Receipt live vaccine within 28 day prior randomization . 7 . Receipt plan receipt investigational vaccine . 8 . Known suspected congenital immunodeficiency . 9 . Receipt immunosuppressive therapy longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) . 10 . Known suspected autoimmune disease 11 . Hypersensitivity vaccine component , history lifethreatening reaction vaccine contain substance vaccine use trial . 12 . Participation another clinical trial investigational product ( IP ) . 13 . Bleeding disorder receipt anticoagulants 3 week precede randomization , contraindicate IM vaccination . 14 . Chronic illness , opinion investigator , stage might interfere trial conduct completion . 15 . Febrile illness ( temperature ≥ 100.4°F [ ≥ 38.0°C ] ) within 24 hour prior randomization . Note : A subject may enroll recovery febrile illness subject still within age window . 16 . Systemic antibiotic use within 48 hour prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>64 Days</minimum_age>
	<maximum_age>196 Days</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>BCG Vaccinated</keyword>
	<keyword>HIV Negative</keyword>
</DOC>